Guidance: Pesticides; Evaluation of Products for Claims against Viruses
Details
The document's own metadata, straight from the source system.
- Title
- Guidance: Pesticides; Evaluation of Products for Claims against Viruses
Federal Register for Thursday, October 10, 2024 (89 FR 82237)(FRL–11108–02– OCSPP) EPA–HQ–OPP–2023–0288Pesticides; Interim Guidance for the Evaluation of Products for Claims Against Viruses; Notice of Availability
- Posted
- Oct 10, 2024
- Comment period
- Oct 10, 2024 – Oct 11, 2032
- FR Doc
- 2024-23471
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Stance breakdown
Who commented
Breakdown by commenter type.
Comments over time
Weekly arrivals, stacked by stance.
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to browse its comments.
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
- Jan 31, 2026Comment submitted by Melisa GeorgeSupportIndividual
The commenter supports the EPA's goal of increasing access to effective products against viruses but argues that the guidance must require more rigorous, use-specific evidence. They emphasize that virucidal claims should only be granted when testing demonstrates efficacy under real-world conditions and at specific labeled concentrations to ensure public safety and environmental protection.
Read comment → - Jan 20, 2026Comment submitted by Camden ReedSupportIndividual
The commenter supports the proposed guidance, stating that products should be allowed to make claims against viruses if there is substantial evidence of effectiveness. They also suggest that companies should be required to update their research and labeling as resistance to these products develops over time.
Read comment → - Dec 13, 2025Comment submitted by Madison GouinSupportIndividual
The commenter supports the EPA's initiative to provide guidance on evaluating pesticide products for claims against viruses. They suggest that the EPA should provide more specific details on efficacy data generation, labeling requirements, environmental stewardship, and transparency in the evaluation process.
Read comment → - Nov 20, 2025Comment submitted by Vika V. (no surname provided)SupportIndividualRead comment →
